US Food and Drug Administration and Regulation Issues for Biologics
Facial Plastic Surgery Clinics of North America · 2026-08 · 34 (3) · 501-507
DOI: 10.1016/j.fsc.2026.05.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Facial Plastic Surgery Clinics of North America, 2026-08. Verfasst von Jeffrey Segal. Beteiligte Einrichtung: Medical Justice Services, Inc., Greensboro, NC, USA. Electronic address: jsegal@medicaljustice.com. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Biological Products, Stem Cell Transplantation. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Stem cell clinics and stem cell use are arguably subject to regulatory oversight at multiple levels including the US Food and Drug Administration (FDA), offices of attorney generals, and state medical licensing boards. Such regulatory oversight has been enforced unevenly. Two high profile appellate court cases propelled by the FDA, Department of Justice criminal prosecutions, and a US Supreme Court decision have reshuffled the deck, auguring over the next several years paradoxically for both more stringent enforcement and less enforcement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Justice Services, Inc., Greensboro, NC, USA. Electronic address: jsegal@medicaljustice.com.
Zitieren
APA
Segal, J. (2026). US Food and Drug Administration and Regulation Issues for Biologics. Facial Plastic Surgery Clinics of North America, 34(3), 501-507. https://doi.org/10.1016/j.fsc.2026.05.006
Vancouver
Segal J. US Food and Drug Administration and Regulation Issues for Biologics. Facial Plastic Surgery Clinics of North America. 2026;34(3):501-507. doi:10.1016/j.fsc.2026.05.006
BibTeX
@article{Segal2026,
author = {Segal, Jeffrey},
title = {US Food and Drug Administration and Regulation Issues for Biologics},
journal = {Facial Plastic Surgery Clinics of North America},
year = {2026},
volume = {34},
number = {3},
pages = {501--507},
doi = {10.1016/j.fsc.2026.05.006}
}
EUVIMED